What is the difference between GLP-2 and Larazotide?

GLP-2: Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Larazotide: Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity

Is GLP-2 FDA approved?

GLP-2 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Larazotide FDA approved?

Larazotide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is GLP-2 administered in research settings?

In research settings, GLP-2 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Larazotide administered in research settings?

In research settings, Larazotide is typically administered via the oral route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-2 vs Larazotide

Peptide Comparison

GLP-2 vs Larazotide

Both are Tissue Repair peptides.

GLP-2

Glucagon-like Peptide-2

RecoveryNot EvaluatedResearch Only

11 providers listed

Full GLP-2 profile →

Larazotide

AT1001

RecoveryInvestigationalResearch Only

Half-life: ~30 minutes (local gut action)

11 providers listed

Full Larazotide profile →

Bottom line

GLP-2 carries stronger published evidence (RCT, 7 key studies) than Larazotide (RCT, 3); both are research compounds.

Quick Verdict

GLP-2

Half-life

—

Larazotide

Half-life

~30 minutes (local gut action)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	GLP-2
Further along in FDA review	Larazotide
Oral administration option	Larazotide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-2

Larazotide

Mechanism Family

Tissue Repair

Half-life

—

~30 minutes (local gut action)

FDA Status

not evaluated

investigational

Admin Routes

subcutaneous

oral

Availability

Research Only

Providers

11 listed

Avail. Notes

Native GLP-2 is not an FDA-approved drug substance; an openFDA ingredient search for "glucagon-like" returns no approved product. The approved product is teduglutide (Gattex, NDA 203441, original approval 2012-12-21), a 33-amino-acid ANALOG of human GLP-2 — see the separate teduglutide profile. The 2012-08-30 date previously carried on this record corresponds to no locatable FDA approval action and has been removed.

Tight junction regulator (AT-1001) for celiac disease. No NDA filed. Phase 3 planned by ImmunoGenX. Investigational.

Research Evidence

GLP-2

RCT · 7 key studies · most recent 2026

Larazotide

RCT · 3 key studies · most recent 2026

Research Citations

GLP-2

RCT2018 · Nutrition in Clinical Practice

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Pa…

Case series2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Cohort2026 · Clin Nutr

Impact of intestinal resections on the secretion of gastrointestinal hormones.

+3 more

Larazotide

RCT2015 · Gastroenterology

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized control…

RCT2012 · American Journal of Gastroenterology

A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during glu…

Animal2026 · Digestion

Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stre…

About GLP-2

Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.

Research Areas

gut lining repairintestinal integritybarrier functionanti-inflammatory

About Larazotide

Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity

Research Areas

tight junction restorationintestinal barrier repairleaky gut prevention

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Larazotide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

GLP-2

11 listed

Browse directory →

Providers offering

Larazotide

11 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.